Qiagen stock: EQT bids above USD 50.00, shares rise pre-market
Published on 10/21/2026 at 07:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTakeover bid enters focus
- EQT submitted a binding offer above USD 50.00 per Qiagen share.
- Bloomberg News said Qiagen's board was meeting during the week of October 20, 2026.
- Qiagen stock trades pre-market at EUR 43.77 at 7:52 a.m. CEST at Lang & Schwarz on October 21, 2026, 2.19 percent above the Xetra close of October 20, 2026.
On October 20, 2026, Bloomberg News reported that EQT AB was in advanced talks to acquire Qiagen N.V. and had submitted a binding offer of more than USD 50.00 per share; KKR & Co. also made a bid. Qiagen stock trades pre-market at EUR 43.77 at 7:52 a.m. CEST at Lang & Schwarz on October 21, 2026, 2.19 percent above the Xetra close of October 20, 2026 (EUR 42.83).
EQT takeover talks
Bloomberg News attributed the acquisition report to people familiar with the matter and said Qiagen's board was meeting during the week. The report added that there was no certainty the discussions would result in a sale to EQT or another buyer. The report also identified KKR as a competing bidder.
Pre-market pricing
The stock is EUR 0.94 above that reference. The bid was EUR 43.50 and the ask EUR 44.05, a spread of 1.26 percent. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Qiagen stock.
Qiagen and today's agenda
QIAGEN develops molecular testing and related laboratory technologies, earning revenue from products and services sold into research and clinical markets, as described in its investor-relations materials. Bloomberg News reported that the board was meeting this week as the potential transaction was considered. Market context: Market report AEX.
